0001193125-23-164443.txt : 20230609 0001193125-23-164443.hdr.sgml : 20230609 20230609160629 ACCESSION NUMBER: 0001193125-23-164443 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230608 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20230609 DATE AS OF CHANGE: 20230609 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IO Biotech, Inc. CENTRAL INDEX KEY: 0001865494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870909276 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41008 FILM NUMBER: 231005271 BUSINESS ADDRESS: STREET 1: OLE MAALOES VEH 3 CITY: COPENHAGEN STATE: G7 ZIP: 2200 BUSINESS PHONE: 4570702980 MAIL ADDRESS: STREET 1: OLE MAALOES VEH 3 CITY: COPENHAGEN STATE: G7 ZIP: 2200 8-K 1 d457839d8k.htm 8-K 8-K
false 0001865494 0001865494 2023-06-08 2023-06-08

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 8, 2023

 

 

IO Biotech, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-41008   87-0909276

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

Ole Maaløes Vej 3

DK-2200 Copenhagen N

Denmark

(Address of Principal Executive Offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code: +45 7070 2980

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   IOBT   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 


Item 5.07.

Submission of Matters to a Vote of Security Holders.

On June 8, 2023, IO Biotech, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). Three items of business were acted upon by the stockholders at the Annual Meeting. The final results for the votes regarding each proposal are set forth below.

Proposal One: Election of Class II Directors

Each of Priyanka Belawat and Christian Elling was elected to serve as a class II director to hold office until the Company’s 2026 Annual Meeting of Stockholders and until the election and qualification of his or her successor. Votes were cast as follows:

 

     For      Withheld      Broker Non-Votes  

Priyanka Belawat, Ph.D.

     18,148,150        1,993,756        789,675  

Christian Elling, Ph.D.

     18,139,833        2,002,073        789,675  

Proposal Two: Amendment to the Certificate of Incorporation to Provide Exculpation for Officers

The stockholders approved an amendment to the Company’s Certificate of Incorporation to provide exculpation for officers by the following vote:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

20,021,960   115,161   4,875   789,675

Proposal Three: Ratification of Appointment of Independent Registered Public Accounting Firm

The stockholders ratified the appointment of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 by the following vote:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

20,815,596   111,302   4,683   —  


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    IO Biotech, Inc.
Date: June 9, 2023     By:  

/s/ Mai-Britt Zocca, Ph.D.

      Mai-Britt Zocca, Ph.D.
      Chief Executive Officer
EX-101.SCH 2 iobt-20230608.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 iobt-20230608_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, City or Town Entity Address, City or Town Entity Address, Country Entity Address, Country City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 iobt-20230608_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
Jun. 08, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001865494
Document Type 8-K
Document Period End Date Jun. 08, 2023
Entity Registrant Name IO Biotech, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-41008
Entity Tax Identification Number 87-0909276
Entity Address, Address Line One Ole Maaløes Vej 3
Entity Address, Postal Zip Code DK-2200
Entity Address, City or Town Copenhagen N
Entity Address, Country DK
City Area Code +45
Local Phone Number 7070 2980
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol IOBT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 6 d457839d8k_htm.xml IDEA: XBRL DOCUMENT 0001865494 2023-06-08 2023-06-08 false 0001865494 8-K 2023-06-08 IO Biotech, Inc. DE 001-41008 87-0909276 Ole Maaløes Vej 3 DK-2200 Copenhagen N DK +45 7070 2980 false false false false Common Stock, par value $0.001 per share IOBT NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d457839d8k.htm iobt-20230608.xsd iobt-20230608_lab.xml iobt-20230608_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d457839d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "d457839d8k.htm" ] }, "labelLink": { "local": [ "iobt-20230608_lab.xml" ] }, "presentationLink": { "local": [ "iobt-20230608_pre.xml" ] }, "schema": { "local": [ "iobt-20230608.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "iobt", "nsuri": "http://www.iobiotech.com/20230608", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d457839d8k.htm", "contextRef": "duration_2023-06-08_to_2023-06-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d457839d8k.htm", "contextRef": "duration_2023-06-08_to_2023-06-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.iobiotech.com//20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001193125-23-164443-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-164443-xbrl.zip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end